A single-arm, open-label, phase II trial of BXCL701, an oral innate immune activator, in combination with Keytruda (pembrolizumab) in patients with small cell neuroendocrine prostate cancer showed positive overall survival data. As of a data cutoff of Sept. 6, evaluable patients with SCNC showed a median OS of 13.6 months, and a 12-month survival rate of 56.5%.
Unfold AI, an AI prostate cancer mapping and clinical decision support platform, is now included in Medicare’s Physician Fee Schedules across the West Coast and Mountain West regions. The regional expansion of Medicare payment for the tool gives urologists and care teams clearer reimbursement pathways in physician office settings, an area that has historically lagged behind hospital outpatient settings for emerging technologies.
